N,O-diacetylephedrine | 55133-90-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N,O-diacetylephedrine
• 英文别名: 2-[Acetyl(methyl)amino]-1-phenylpropyl acetate；[2-[acetyl(methyl)amino]-1-phenylpropyl] acetate
• CAS: 55133-90-9
• 化学式: C₁₄H₁₉NO₃
• 分子量: 249.31
• InChiKey: DISCLSGXBAXBTJ-UHFFFAOYSA-N

物化性质

• 沸点：
  168 °C(Press: 3 Torr)
• 密度：
  1.082±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2924299090

文献信息

• SUBSTITUTED AMINO ALCOHOLS AS CHIRAL DOPANTS
  申请人：Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung E.V.

  公开号：US20140228591A1

  公开（公告）日：2014-08-14

  The invention relates to the use of a substituted, chiral amino alcohol, comprising one or more structural units of the following formula (1), wherein the abbreviations A, Y, R1 and R3 to R5 have the following meanings: is a covalent bond or a hydrocarbon group, Y is a covalent bond or a hydrocarbon group that can have an oxygen atom at one of its ends through which it is bonded to R 1 , R 1 is an aliphatic or heterocyclic or aromatic radical, the carbon chain of which may be interrupted by one or more B groups, R 5 is selected from the group consisting of (a) aliphatic radicals, wherein individual carbon atoms may be replaced by oxygen atoms or carbonyl groups, and wherein the carbon chains of same radicals may be optionally interrupted by a B group, and (b) araliphatic, cycloaliphatic, aromatic and heterocyclic radicals, wherein the carbon chain can be interrupted by one or more B structural elements and/or by one or more D coupling groups, R 3 , R 4 are hydrogen or aliphatic or araliphatic substituents, which are independent of one another, wherein the carbon chain can be interrupted by one or more B groups, B is selected from polymerizable or crosslinkable structural elements from the group comprising C 1 -C 16 -alkenyl, C 1 -C 16 -alkenyloxy, —C═C—, —CH═CH—COO—, —CH═CH—, —CX═CH—COO— with X═C 1 -C 16 -alkyl, and the trans-form of —OOC—CH═CH—COO—, and D is selected from —O—, —NH—, —N(CH 3 )—, —N(C 2 H 5 )—, —SO 2 —, —CO—, —COO—, —CH═CH—, —OCOO—, —OCH 2 —, CH═N, —CF 2 CF 2 —, as a chiral dopant in liquid crystal (mixtures), e.g., in electro-optical systems.
• ORAL BILAYER TABLETS COMPRISING ACETYLSALICYLIC ACID AND PSEUDOEPHEDRINE, METHODS OF PREPARING AND USING THEREOF
  申请人：Bayer HealthCare LLC

  公开号：US20220151936A1

  公开（公告）日：2022-05-19

  The present disclosure relates generally to bilayer tablets comprising a combination of two active pharmaceutical ingredients, and more specifically to bilayer tablets comprising acetylsalicylic acid, pseudoephedrine, and a dissolution aid. The bilayer tablets utilize a combination of granulated and non-granulated acetylsalicylic acid along with a unique distribution of sodium carbonate as a dissolution aid that provide acetylsalicylic acid and pseudoephedrine in a single dosage form having rapid dissolution and long-term storage stability (low degradation). The present disclosure also provides methods of preparing and of using the bilayer tablets.
• US9273247B2
  申请人：——

  公开号：US9273247B2

  公开（公告）日：2016-03-01
• [EN] ORAL BILAYER TABLETS COMPRISING ACETYLSALICYLIC ACID AND PSEUDOEPHEDRINE, METHODS OF PREPARING AND USING THEREOF<br/>[FR] COMPRIMÉS BICOUCHES ORAUX COMPRENANT DE L'ACIDE ACÉTYLSALICYLIQUE ET DE LA PSEUDOÉPHÉDRINE, LEURS MÉTHODES DE PRÉPARATION ET D'UTILISATION
  申请人：[en]BAYER HEALTHCARE LLC

  公开号：WO2022103620A1

  公开（公告）日：2022-05-19

  The present disclosure relates generally to bilayer tablets comprising a combination of two active pharmaceutical ingredients, and more specifically to bilayer tablets comprising acetylsalicylic acid, pseudoephedrine, and a dissolution aid. The bilayer tablets utilize a combination of granulated and non-granulated acetylsalicylic acid along with a unique distribution of sodium carbonate as a dissolution aid that provide acetylsalicylic acid and pseudoephedrine in a single dosage form having rapid dissolution and long-term storage stability (low degradation). The present disclosure also provides methods of preparing and of using the bilayer tablets.